{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:29:18Z","timestamp":1786350558688,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00415-026-13988-7","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:08:25Z","timestamp":1783948105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical course of critical demyelinating lesion-associated progressive multiple sclerosis"],"prefix":"10.1007","volume":"273","author":[{"given":"Tuba S.","family":"Chaudhry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeela","family":"Nathoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Albites","family":"Coen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purnashree","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowaid","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin S.","family":"Jackson-Tarlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lucchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Oliver","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhun H.","family":"Kantarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-935X","authenticated-orcid":false,"given":"B. Mark","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"6","key":"13988_CR1","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1177\/1352458520940983","volume":"27","author":"RM Kassa","year":"2021","unstructured":"Kassa RM et al (2021) Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Mult Scler 27(6):895\u2013902","journal-title":"Mult Scler"},{"issue":"11","key":"13988_CR2","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1177\/1352458518781979","volume":"24","author":"BM Keegan","year":"2018","unstructured":"Keegan BM et al (2018) Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. Mult Scler 24(11):1445\u20131452","journal-title":"Mult Scler"},{"key":"13988_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/B978-0-323-98817-9.00016-8","volume":"196","author":"DS Younger","year":"2023","unstructured":"Younger DS (2023) Multiple sclerosis: motor dysfunction. Handb Clin Neurol 196:119\u2013147","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"13988_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/13524585221114438","volume":"29","author":"CS Jackson-Tarlton","year":"2023","unstructured":"Jackson-Tarlton CS et al (2023) Progressive motor impairment from \u201ccritical\u201d demyelinating lesions of the cervicomedullary junction. Mult Scler 29(1):74\u201380","journal-title":"Mult Scler"},{"issue":"16","key":"13988_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1212\/WNL.0000000000003235","volume":"87","author":"BM Keegan","year":"2016","unstructured":"Keegan BM et al (2016) Progressive solitary sclerosis: gradual motor impairment from a single CNS demyelinating lesion. Neurology 87(16):1713\u20131719","journal-title":"Neurology"},{"issue":"7","key":"13988_CR6","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1212\/WNL.0000000000007944","volume":"93","author":"E Sechi","year":"2019","unstructured":"Sechi E et al (2019) Unilateral motor progression in MS: association with a critical corticospinal tract lesion. Neurology 93(7):e628\u2013e634","journal-title":"Neurology"},{"issue":"10","key":"13988_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00415-025-13322-7","volume":"272","author":"R Ahmad","year":"2025","unstructured":"Ahmad R et al (2025) Critical demyelinating lesions in progressive multiple sclerosis: a prospective observational study. J Neurol 272(10):677","journal-title":"J Neurol"},{"issue":"2","key":"13988_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"issue":"11","key":"13988_CR9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452","journal-title":"Neurology"},{"key":"13988_CR10","unstructured":"Jackson-Tarlton, C.S., et al. A prospective study of \u201ccritical\u201d demyelinating lesions causing progressive motor impairment in multiple sclerosis. in ECTRIMS. 2023. Milan, Italy: Multiple Sclerosis Journal."},{"issue":"7","key":"13988_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3174\/ajnr.A8304","volume":"45","author":"BM Keegan","year":"2024","unstructured":"Keegan BM et al (2024) MR imaging features of critical spinal demyelinating lesions associated with progressive motor impairment. AJNR Am J Neuroradiol 45(7):943\u2013950","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"13988_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00415-025-13106-z","volume":"272","author":"L Cacciaguerra","year":"2025","unstructured":"Cacciaguerra L et al (2025) Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple sclerosis. J Neurol 272(5):367","journal-title":"J Neurol"},{"issue":"2","key":"13988_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL et al (2019) Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321(2):175\u2013187","journal-title":"JAMA"},{"issue":"5","key":"13988_CR14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding K et al (2019) Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 76(5):536\u2013541","journal-title":"JAMA Neurol"},{"issue":"4","key":"13988_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19(4):307\u2013316","journal-title":"Lancet Neurol"},{"key":"13988_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104220","volume":"68","author":"H Tedeholm","year":"2022","unstructured":"Tedeholm H et al (2022) Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis. Mult Scler Relat Disord 68:104220","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"13988_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1212\/WNL.0000000000001856","volume":"85","author":"M Novotna","year":"2015","unstructured":"Novotna M et al (2015) Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology 85(8):722\u2013729","journal-title":"Neurology"},{"issue":"4","key":"13988_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/1352458517736147","volume":"24","author":"I Dekker","year":"2018","unstructured":"Dekker I et al (2018) Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis. Mult Scler 24(4):481\u2013490","journal-title":"Mult Scler"},{"issue":"12","key":"13988_CR19","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1007\/s00415-019-09526-3","volume":"266","author":"F Granella","year":"2019","unstructured":"Granella F et al (2019) Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey. J Neurol 266(12):3031\u20133037","journal-title":"J Neurol"},{"key":"13988_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030463","author":"C Ostini","year":"2021","unstructured":"Ostini C et al (2021) Recurrence and prognostic value of asymptomatic spinal cord lesions in multiple sclerosis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10030463","journal-title":"J Clin Med"},{"issue":"10","key":"13988_CR21","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1007\/s00415-023-11829-5","volume":"270","author":"S Ruggieri","year":"2023","unstructured":"Ruggieri S et al (2023) The added value of spinal cord lesions to disability accrual in multiple sclerosis. J Neurol 270(10):4995\u20135003","journal-title":"J Neurol"},{"issue":"4\u20135","key":"13988_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/13524585241228426","volume":"30","author":"TRU Lim","year":"2024","unstructured":"Lim TRU et al (2024) Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis. Mult Scler 30(4\u20135):505\u2013515","journal-title":"Mult Scler"},{"key":"13988_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251331405","author":"Y Fadlallah","year":"2025","unstructured":"Fadlallah Y et al (2025) Frequency and potential risk factors associated with the development of asymptomatic T2 hyperintense cervical spine lesions on MRI in patients with relapsing-remitting multiple sclerosis. Mult Scler. https:\/\/doi.org\/10.1177\/13524585251331405","journal-title":"Mult Scler"},{"issue":"2","key":"13988_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ana.24564","volume":"79","author":"OH Kantarci","year":"2016","unstructured":"Kantarci OH et al (2016) Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. Ann Neurol 79(2):288\u2013294","journal-title":"Ann Neurol"},{"issue":"8","key":"13988_CR25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1212\/WNL.0b013e31820d8b1d","volume":"76","author":"DT Okuda","year":"2011","unstructured":"Okuda DT et al (2011) Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 76(8):686\u2013692","journal-title":"Neurology"},{"issue":"10","key":"13988_CR26","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1136\/jnnp-2013-306906","volume":"85","author":"C Jacobsen","year":"2014","unstructured":"Jacobsen C et al (2014) Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry 85(10):1109\u20131115","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13988_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104714","volume":"74","author":"PM Matthews","year":"2023","unstructured":"Matthews PM et al (2023) The association between brain volume loss and disability in multiple sclerosis: A systematic review. Mult Scler Relat Disord 74:104714","journal-title":"Mult Scler Relat Disord"},{"issue":"13","key":"13988_CR28","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1177\/1352458516629769","volume":"22","author":"R Zivadinov","year":"2016","unstructured":"Zivadinov R et al (2016) A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult Scler 22(13):1709\u20131718","journal-title":"Mult Scler"},{"issue":"3","key":"13988_CR29","doi-asserted-by":"publisher","first-page":"fdae158","DOI":"10.1093\/braincomms\/fcae158","volume":"6","author":"ES Beck","year":"2024","unstructured":"Beck ES et al (2024) Contribution of new and chronic cortical lesions to disability accrual in multiple sclerosis. Brain Commun 6(3):fdae158","journal-title":"Brain Commun"},{"issue":"Pt 10","key":"13988_CR30","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1093\/brain\/aws246","volume":"135","author":"M Calabrese","year":"2012","unstructured":"Calabrese M et al (2012) Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 135(Pt 10):2952\u20132961","journal-title":"Brain"},{"issue":"3","key":"13988_CR31","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1148\/radiol.2019181719","volume":"291","author":"CA Treaba","year":"2019","unstructured":"Treaba CA et al (2019) Longitudinal characterization of cortical lesion development and evolution in multiple sclerosis with 7.0-T MRI. Radiology 291(3):740\u2013749","journal-title":"Radiology"},{"issue":"4-5","key":"13988_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1177\/13524585241229956","volume":"30","author":"JA Reeves","year":"2024","unstructured":"Reeves JA et al (2024) Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years. Mult Scler 30(4\u20135):535\u2013545","journal-title":"Mult Scler"},{"key":"13988_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2024.110810","volume":"129","author":"A Toru Asahina","year":"2024","unstructured":"Toru Asahina A et al (2024) Prognostic significance of paramagnetic rim lesions in multiple sclerosis: a systematic review. J Clin Neurosci 129:110810","journal-title":"J Clin Neurosci"},{"key":"13988_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106804","volume":"104","author":"LA Zarco","year":"2025","unstructured":"Zarco LA et al (2025) Paramagnetic iron rim lesions as a prognostic factor for disability progression in multiple sclerosis: a systematic review of the literature. Mult Scler Relat Disord 104:106804","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"13988_CR35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3174\/ajnr.A5495","volume":"39","author":"FX Aymerich","year":"2018","unstructured":"Aymerich FX et al (2018) Cervical cord atrophy and long-term disease progression in patients with primary-progressive multiple sclerosis. AJNR Am J Neuroradiol 39(2):399\u2013404","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"13988_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/ana.26281","volume":"91","author":"A Bischof","year":"2022","unstructured":"Bischof A et al (2022) Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. Ann Neurol 91(2):268\u2013281","journal-title":"Ann Neurol"},{"issue":"2","key":"13988_CR37","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000435","volume":"5","author":"B Zeydan","year":"2018","unstructured":"Zeydan B et al (2018) Cervical spinal cord atrophy: an early marker of progressive MS onset. Neurol Neuroimmunol Neuroinflamm 5(2):e435","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13988_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106318","volume":"95","author":"SA Banks","year":"2025","unstructured":"Banks SA et al (2025) Progressive unilateral tremor associated with large confluent perirolandic juxtacortical lesions in multiple sclerosis. Mult Scler Relat Disord 95:106318","journal-title":"Mult Scler Relat Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13988-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13988-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13988-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:49:28Z","timestamp":1786348168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13988-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["13988"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13988-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tuba Chaudhry, Bianca Albites Cohen, Purnashree Chowdhury, Rowaid Ahmad, and Steven Messina declare that they have no conflict of interest. Nabeela Nathoo reports research funding from MS Canada, consulting and\/or advisory board participation for Novartis, Roche, and EMD Serono. Caitlin Jackson-Tarlton reports speaking, consulting, and\/or advisory board participation for Novartis, Biogen, EMD Serono, Hoffmann La Roche, and Amgen Horizon unrelated to the current work. Eoin Flanagan reports advisory boards for Alexion, Genentech, Horizon Therapeutics and UCB, research support from UCB, royalties from UpToDate, site principal investigator in a randomized clinical trial of Rozanolixizumab for relapsing myelin oligodendrocyte glycoprotein antibody-associated disease run by UCB, site principal investigator and a member of the steering committee for a clinical trial of satralizumab for relapsing myelin oligodendrocyte glycoprotein antibody-associated disease run by Roche\/Genentech, Co-Investigator on a study of ravulizumab for neuromyelitis optica spectrum disorder run by Alexion, has given educational talks on neuromyelitis optica spectrum disorder funded by Alexion, has received funding from the NIH (R01NS113828), honoraria for editing and writing articles for The Continuum Lifelong Learning in Neurology Journal, member of the medical advisory board of the MOG project and Sumaira Foundation, editorial board member of Neurology, Neuroimmunology and Neuroinflammation, The Journal of the Neurological Sciences and Neuroimmunology Reports, and patent submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity. Claudia Lucchinetti reports grant support from NIH and NINDS, Patent Number: US 11219402 Imaging biomarkers of neurologic disease, and Patent Number: 7101679 NMO-IGG: marker autoantibody of neuromyelitis optica. Sean Pittock reports grants or contracts from Alexion, AMGEN, and Roche, all paid directly to Mayo Clinic, and a co-investigator grant from NIH (R01NS113828). He has received royalties from a patent related to neuromyelitis optica spectrum disorder (NMOSD; Patent# 9,891,219B2), personal compensation from Arialys, consulting fees from Alexion, Amgen, and UCB, all paid directly to Mayo Clinic, and support for attending meetings or travel from Alexion for providing lectures for Alexion-run Symposia and attending NMOSD Advisory Board Meetings. He reports patents issued (Patent# 8,889,102 and Patent# 9,891,219B2) and pending (GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, PDE10A, Cav4, Dashund, and Septin). He has participated on Advisory Boards for UCB (compensation to institution), Hoffman\/LaRoche AG (compensation to institution), Alexion (compensation to institution) and Genentech (compensation to institution). W. Oliver Tobin reports research funding from NIH and Mayo Clinic Center for MS and Autoimmune Neurology, and book royalties from Oxford University Press. Michel Toledano reports grant support from NINDS and serves on the Advisory Editorial Board of The Neurohospitalist. Brian Weinshenker reports being the chair of attack adjudication committees for clinical trials in neuromyelitis optica spectrum disorders for Alexion, VielaBio\/Horizon Therapeutics, and UCB Biosciences, consulted with Genentech, Roche and CANbridge Pharmaceuticals regarding clinical trial designs for neuromyelitis optica spectrum disorders, speaking fees from Genentech, Horizon Therapeutics, Roche and Mitsubishi Tanabe, patent for NMO-IgG for diagnosis of neuromyelitis optica, and royalties paid by Hospice Civil de Lyon, MVZ PD Dr. Volkmann und Kollegen GbR, Oxford University and RSR Limited. Orhun Kantarci reports research support from PCORI, UK MS Society, NMSS, NIAID, NINDS, and book royalties Oxford University Press. B. Mark Keegan reports consulting for Moderna, EMD Serono, Tr1X, Inc, book royalties Oxford University Press, and philanthropic support from Mr. Ryan N. Lambert and Family.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the Mayo Foundation Institutional Review Board (No. 09007045) and with the Helsinki Declaration of 1975, as revised in 2000.","order":2,"name":"Ethics","label":"Ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"456"}}